This can be explained by the fact that HF management and coronary disease require distinct therapeutic strategies [24, 25], and finerenone's primary action on the mineralocorticoid receptor may not address the underlying atherosclerotic processes that drive MI [26, 27]. The gene discussed is NR3C2; the disease is coronary artery disorder.